Evidence map›Paper›PMID 40201722›Full record

ArticleOpen forum infectious diseases2025

Epidemiology of Group B

Mary Kyohere, Hannah Georgia Davies, Konstantinos Karampatsas, Liberty Cantrell, Philippa Musoke, Annettee Nakimuli, Valerie Tusubira, Juliet Sendagala Nsimire, Dorota Jamrozy, Uzma Basit Khan and 19 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Prevalence of Group BMedical sciences (Basel, Switzerland) · 2026
    Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Mary KyohereMakerere University-Johns Hopkins University Research Collaboration, Kampala, Uganda.
Hannah Georgia DaviesCentre for Neonatal and Paediatric Infection, Institute of Infection and Immunity, City St George's, University of London, London, United Kingdom.
Konstantinos KarampatsasCentre for Neonatal and Paediatric Infection, Institute of Infection and Immunity, City St George's, University of London, London, United Kingdom.ORCID https://orcid.org/0000-0002-5313-9482
Liberty CantrellOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom.ORCID https://orcid.org/0000-0001-5413-7641
Philippa MusokeMakerere University-Johns Hopkins University Research Collaboration, Kampala, Uganda.
Annettee NakimuliDepartment of Obstetrics and Gynaecology, College of Health Sciences, Makerere University, Kampala, Uganda.ORCID https://orcid.org/0000-0003-2806-0243
Valerie TusubiraMakerere University-Johns Hopkins University Research Collaboration, Kampala, Uganda.ORCID https://orcid.org/0000-0002-3395-8755
Juliet Sendagala NsimireClinical Diagnostics Laboratories, MRC/UVRI/LSHTM, Entebbe, Uganda.
Dorota JamrozyParasites and Microbes Programme, Wellcome Sanger Institute, Hinxton, United Kingdom.ORCID https://orcid.org/0000-0002-5703-9315
Uzma Basit KhanParasites and Microbes Programme, Wellcome Sanger Institute, Hinxton, United Kingdom.
Stephen D BentleyParasites and Microbes Programme, Wellcome Sanger Institute, Hinxton, United Kingdom.
Owen B SpillerDivision of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, United Kingdom.ORCID https://orcid.org/0000-0002-9117-6911
Caitlin FarleyDivision of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, United Kingdom.ORCID https://orcid.org/0009-0006-5309-2991
Tom HallCentre for Neonatal and Paediatric Infection, Institute of Infection and Immunity, City St George's, University of London, London, United Kingdom.ORCID https://orcid.org/0000-0002-9001-6684
Olwenn DanielCentre for Neonatal and Paediatric Infection, Institute of Infection and Immunity, City St George's, University of London, London, United Kingdom.ORCID https://orcid.org/0000-0002-6997-1839
Simon BeachCentre for Neonatal and Paediatric Infection, Institute of Infection and Immunity, City St George's, University of London, London, United Kingdom.ORCID https://orcid.org/0009-0004-6234-6362
Nick AndrewsUK Health Security Agency, London, United Kingdom.
Stephanie J SchragNational Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Clare L CutlandWits African Leadership in Vaccinology Expertise, School of Pathology, Faculty of Health Science, University of the Witwatersrand, Johannesburg, South Africa.
Andrew GorringePathogen Immunology Group, UK Health Security Agency, Salisbury, United Kingdom.ORCID https://orcid.org/0000-0003-2193-7954
Stephanie LeungPathogen Immunology Group, UK Health Security Agency, Salisbury, United Kingdom.ORCID https://orcid.org/0000-0002-8880-2977
Stephen TaylorPathogen Immunology Group, UK Health Security Agency, Salisbury, United Kingdom.
Paul T HeathCentre for Neonatal and Paediatric Infection, Institute of Infection and Immunity, City St George's, University of London, London, United Kingdom.
Stephen CoseMedical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda.ORCID https://orcid.org/0000-0002-5156-037X
Carol BakerMcGovern Medical School, University of Texas Health Science Center, Houston, Texas, USA.
Merryn VoyseyOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom.ORCID https://orcid.org/0000-0001-6324-6559
Kirsty Le DoareCentre for Neonatal and Paediatric Infection, Institute of Infection and Immunity, City St George's, University of London, London, United Kingdom.
Musa SekikuboDepartment of Obstetrics and Gynaecology, College of Health Sciences, Makerere University, Kampala, Uganda.
PROGRESS Study Group

Funding

Gates Foundation INV-010426
6 · The paper itself

Abstract

Background: Child survival rates have improved globally, but neonatal mortality due to infections, such as group B Methods: We assessed maternal rectovaginal GBS colonization and neonatal disease rates in a prospective cohort of 6062 women-infant pairs. Surveillance for invasive infant disease occurred in parallel at 2 Kampala hospital sites. In a nested case-control study, we identified infants <90 days of age with invasive GBS disease (iGBS) (n = 24) and healthy infants born to mothers colonized with GBS (n = 72). We measured serotype-specific anticapsular immunoglobulin G (IgG) in cord blood/infant sera using a validated multiplex Luminex assay. Results: We found a high incidence of iGBS (1.0 per 1000 live births) within the first 90 days of life across the surveillance sites, associated with a high case fatality rate (18.2%). Maternal GBS colonization prevalence was consistent with other studies in the region (14.7% [95% confidence interval, 13.7%-15.6%]). IgG geometric mean concentrations were lower in cases than controls for serotypes Ia (0.005 vs 0.12 µg/mL; Conclusions: We found that GBS is an important cause of neonatal and young infant disease in Uganda and confirmed that maternally derived antibodies were lower in early-onset GBS cases than in healthy exposed controls.

Indexed as

anticapsular antibodycorrelate of protectiongroup B Streptococcusinvasive diseaserisk reduction

Identifiers

PMID40201722
PMCPMC11977330

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.